Clinical trial · Observational
Psychometric Properties of the EORTC QLQ-LC29
An International Phase 4 Field Study for Analyzing the Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Lung Cancer (EORTC QLQ-LC29)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the Phase 4 study is to test the scale structure, reliability, responsiveness to change and validity of the EORTC QLQ-LC29 in conjunction with the EORTC QLQ-C30 in patients diagnosed with lung cancer. Participants will be enrolled in four groups according to their primary therapy (A. Surgery, B. Radiochemotherapy, C. Targeted therapy, D. Immunotherapy). According to sample size calculations the investigators will include a total of N = 450 patients, but inflating the recruitment goal is permissible.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunotherapy | Other | — | UNRESOLVED |
| Radiochemotherapy | Other | — | UNRESOLVED |
| Surgery | Other | — | UNRESOLVED |
| Targeted therapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- A. Surgery
- description
- A.1 Surgery alone and/or before any adjuvant therapy A.2 Surgery (late effects)
- interventionNames
- Other: Surgery
- label
- B. Radiochemotherapy
- description
- B.1 Chemotherapy alone B.2 Radiotherapy alone B.3 Sequential radiochemotherapy B.4 Concurrent radiochemotherapy
- interventionNames
- Other: Radiochemotherapy
- label
- C. Targeted therapy
- description
- C.1 Targeted therapy alone C.2 Targeted therapy in combination with any other therapy
- interventionNames
- Other: Targeted therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed diagnosis of lung cancer * no previous primary or recurrent tumour * ability to understand the language of the questionnaire * mental fitness to complete a questionnaire * 18 years of age or above * written informed consent.- Exclusion Criteria: * no histologically confirmed diagnosis of lung cancer- * previous primary or recurrent tumour * not mentally fit to complete a questionnaire * not able to understand the language of the questionnaire * younger than 18 * refusal of informed consent.
References
Publications (2)
- DERIVEDKoch M, Grafenstein L, Karnosky J, Schulz C, Koller M. Psychosocial Burden and Quality of Life of Lung Cancer Patients: Results of the EORTC QLQ-C30/QLQ-LC29 Questionnaire and Hornheide Screening Instrument. Cancer Manag Res. 2021 Aug 7;13:6191-6197. doi: 10.2147/CMAR.S314310. eCollection 2021. PMID 34393512
- DERIVEDKoller M, Shamieh O, Hjermstad MJ, Hornslien K, Young T, Chalk T, Ioannidis G, Harle A, Johnson CD, Tomaszewski KA, Serpentini S, Pinto M, van der Weijst L, Janssens A, Morag O, Chie WC, Arraras JI, Pompili C, Jungraithmayr W, Hechtner M, Katsochi D, Muller K, Grafenstein L, Schulz C, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; EORTC Lung Cancer Group; European Society of Thoracic Surgeons. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study. Lancet Oncol. 2020 May;21(5):723-732. doi: 10.1016/S1470-2045(20)30093-0. Epub 2020 Mar 23. PMID 32213338